Immunovant (IMVT) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Immunovant (IMVT) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 98.9% versus a loss of 10.5%. Over five years, RYTM leads with a +682.1% price change compared with +267.4% for IMVT. Immunovant is the larger company by market cap ($6.62 billion vs $6.09 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMVT | RYTM |
|---|---|---|
| Share price | $32.04 | $88.45 |
| Market cap | $6.62B | $6.09B |
| 1-day change | -0.22% | -2.56% |
| YTD return | +26.04% | -16.49% |
| 1-year return | +98.88% | -10.46% |
| 5-year return | +267.43% | +682.05% |
| EPS (TTM) | $-2.82 | $-3.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $189.76M |
| Revenue growth (YoY) | — | +45.83% |
| Net income (latest FY) | $-505.61M | $-196.54M |
| Gross margin | — | 89.73% |
| Operating margin | — | -101.19% |
| Net margin | — | -103.57% |
| 52-week high | $45.42 | $122.20 |
| 52-week low | $16.04 | $74.50 |
| Distance from 52-week high | -29.46% | -27.62% |
| Analyst consensus | buy | none |
| Avg. price target upside | +52.56% | +56.69% |
| Average volume | 1.23M | 646.31K |
| Shares outstanding | 206.55M | 68.85M |
| Employees | 315 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMVT has outperformed RYTM by 109.3 percentage points over the past year.
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
IMVT vs RYTM FAQ
Which is bigger, Immunovant or Rhythm Pharmaceuticals?
Immunovant (IMVT) is larger, with a market capitalization of $6.62B compared with $6.09B for Rhythm Pharmaceuticals (RYTM).
Which stock has performed better over the past year, IMVT or RYTM?
IMVT returned +98.88% over the past 12 months, compared with -10.46% for RYTM (price return, excluding dividends). Past performance does not predict future results.
Are Immunovant and Rhythm Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Immunovant and Biotechnology: Pharmaceutical Preparations for Rhythm Pharmaceuticals.